Efficacy of Tezepelumab in Peanut Oral Immunotherapy
Public ClinicalTrials.gov record NCT07015996. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial
Study identification
- NCT ID
- NCT07015996
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Interventions
- Peanut Oral Immunotherapy (OIT) Drug
- Placebo for Tezepelumab Biological
- Tezepelumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 12 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2026
- Primary completion
- Sep 15, 2028
- Completion
- Sep 15, 2028
- Last update posted
- Apr 28, 2026
2026 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology | Little Rock | Arkansas | 72202 | — |
| University of California, Los Angeles: Department of Medicine, Division of Clinical Immunology and Allergy | Los Angeles | California | 90095 | — |
| Johns Hopkins Children's Center: Department of Allergy & Immunology | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital: Department of Medicine: Allergy & Clinical Immunology Unit | Boston | Massachusetts | 02114 | — |
| Boston Children's Hospital: Allergy and Asthma Program | Boston | Massachusetts | 02115 | — |
| The University of Michigan: Division of Allergy and Clinical Immunology | Ann Arbor | Michigan | 48105 | — |
| Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology | New York | New York | 10029-6574 | — |
| North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology | Chapel Hill | North Carolina | 27599 | — |
| Cincinnati Children's Hospital Medical Center: Division of Allergy and Immunology | Cincinnati | Ohio | 45229 | — |
| University of Texas Southwestern Medical Center: Division of Allergy and Immunology | Dallas | Texas | 75390-9063 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07015996, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07015996 live on ClinicalTrials.gov.